Last updated on June 2018

Trial to Assess the Pharmacokinetics Safety Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders


Brief description of study

A study to assess pharmacokinetics, safety and tolerability of brexpiprazole in children ages 6 to <13 years with CNS disorders.

Detailed Study Description

A US based nonrandomized, sequential cohort, crossover trial to assess pharmacokinetics, safety and tolerability of brexpiprazole in children ages 6 to <13 years with CNS disorders who are receiving antipsychotic treatment for their medical condition.

Clinical Study Identifier: NCT03292848

Contact Investigators or Research Sites near you

Start Over

Erin Foster

Woodland International Research Group
Little Rock, AR United States

Erin Foster

Woodland Research Northwest, LLC
Rogers, AR United States

Erin Foster

Alliance for Wellness dba Alliance for Research
Long Beach, CA United States

Erin Foster

New Hope Clinical Research
Charlotte, NC United States

Erin Foster

IPS Research Company
Oklahoma City, OK United States

Erin Foster

Cutting Edge Research Group
Oklahoma City, OK United States

Erin Foster

Clinical Trials of Texas, Inc.
San Antonio, TX United States

Erin Foster

Road Runner Research Ltd.
San Antonio, TX United States

Erin Foster

Aspen Clinical Research
Orem, UT United States